// App-Quantinova.ai

P521 : Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenanc

Researchers

Presenter

  • Parkes, G

Principal Investigators

  • Ungaro, R

  • Danese, S

  • Abreu, M

  • Arenson, E

  • Zhou, W

  • Ilo, D

  • Laroux, F.S

  • Deng, H

  • Sanchez Gonzalez, Y

  • Peyrin-Biroulet, L

Medical Centers

  • Barts Health NHS Trust & Barts and the London School of Medicine & Dentistry, London, UK, London, United Kingdom

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy

  • Division of Gastroenterology- Crohn's and Colitis Center- University of Miami Miller School of Medicine, n/a, Miami, United States

  • Adelphi Values, n/a, Boston, United States

  • AbbVie Inc., n/a, North Chicago, United States

  • AbbVie Bioresearch Center, Biologics Discovery, Worcester, United States

  • AbbVie Inc. and Department of Pharmacy Systems Outcomes and Policy- University of Illinois at Chicago, n/a, Chicago, United States

  • University Hospital of Nancy- Lorraine University, n/a, Vandoeuvre, France

Locations

  • United Kingdom

  • United States

  • Italy

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved